Breast Cancer Index-test

Breast Cancer Index^®

Predictive And Prognostic Information For Extended Endocrine Therapy Decision-Making

Breast Cancer Index (BCI) is THE ONLY commercially available test validated to inform the decision regarding extended endocrine therapy based on:

Predictive
Result:

Is she likely to benefit from extended endocrine therapy?

Reported as YES (High Benefit) vs NO (Low Benefit)

Prognostic
Result:

What is her risk of late distant recurrence?

Reported as an individualized percentage risk of late distant recurrence

Supported by Extensive Clinical Evidence for Extended Endocrine Therapy Decision-Making

BCI Predictive

BCI has demonstrated reproducible predictive performance for endocrine therapy response. BCI Predictive validations included patients with both node-negative and node-positive disease.

BCI Prognostic

The ability of BCI to determine an individual’s risk of late distant recurrence has been validated across multiple studies, including various treatment histories, and a mix of pre- and post- menopausal patients.

In one test, BCI combines two complementary gene-expression signatures to assess proliferative and estrogen signaling pathways.^1-5

BCI Predictive

Molecular assessment of estrogen signaling pathways
Genes: HOXB13/IL17BR (H/I)

BCI Prognostic

Algorithmic combination of Molecular Grade Index (MGI: proliferation) and HOXB13/IL17BR (H/I: estrogen signaling pathway)
Genes: BUB1B, CENPA, NEK2, RACGAP1, RRM2, HOXB13/IL17BR (H/I)
For N1 patients: Risk is determined by incorporating the tumor size and grade with the BCI gene expression signature³

References: 1. Zhang Y, et al. Clin Cancer Res. 2013;19: 4196-4205. 2. Sgroi DC, et al. Lancet Oncol. 2013;14: 1067-76. 3. Zhang Y et al. Clin Cancer Res. 2017 Dec 1;23(23):7217-7224. 4. Sgroi DC, et al. J Natl Cancer Inst. 2013;105: 1036-1042. 5. Bartlett et al. Annals of Oncol 2019 doi: 10. 1093/annonc/mdz289.

Back To All

It's Time
For A Change.